Acarix AB (publ) (ACARIX.ST)
SEK 0.25
(-4.05%)
SEK 0.25
(-4.05%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -35.14 Million SEK | -451.79% |
| 2022 | -6.37 Million SEK | 58.33% |
| 2021 | -15.28 Million SEK | 75.62% |
| 2020 | -62.69 Million SEK | -18.45% |
| 2019 | -52.93 Million SEK | 18.53% |
| 2018 | -64.96 Million SEK | 37.17% |
| 2017 | -103.4 Million SEK | 29.12% |
| 2016 | -145.89 Million SEK | -6778.6% |
| 2015 | -2.12 Million SEK | 75.63% |
| 2014 | -8.7 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -48.27 Million SEK | 24.49% |
| 2024 Q1 | -63.92 Million SEK | -81.87% |
| 2023 Q1 | -15.82 Million SEK | -148.35% |
| 2023 Q3 | -9.2 Million SEK | 64.86% |
| 2023 Q2 | -26.19 Million SEK | -65.59% |
| 2023 Q4 | -35.14 Million SEK | -281.89% |
| 2023 FY | -35.14 Million SEK | -451.79% |
| 2022 Q4 | -6.37 Million SEK | 78.09% |
| 2022 Q2 | -49.94 Million SEK | 26.87% |
| 2022 Q1 | -68.29 Million SEK | -346.76% |
| 2022 FY | -6.37 Million SEK | 58.33% |
| 2022 Q3 | -29.07 Million SEK | 41.78% |
| 2021 Q1 | -53.94 Million SEK | 13.96% |
| 2021 FY | -15.28 Million SEK | 75.62% |
| 2021 Q2 | -38.26 Million SEK | 29.08% |
| 2021 Q3 | -27.98 Million SEK | 26.86% |
| 2021 Q4 | -15.28 Million SEK | 45.37% |
| 2020 Q1 | -43.22 Million SEK | 18.35% |
| 2020 FY | -62.69 Million SEK | -18.45% |
| 2020 Q2 | -33.77 Million SEK | 21.86% |
| 2020 Q3 | -75.01 Million SEK | -122.12% |
| 2020 Q4 | -62.69 Million SEK | 16.42% |
| 2019 Q4 | -52.93 Million SEK | -99.51% |
| 2019 FY | -52.93 Million SEK | 18.53% |
| 2019 Q3 | -26.53 Million SEK | 29.26% |
| 2019 Q2 | -37.5 Million SEK | 24.72% |
| 2019 Q1 | -49.81 Million SEK | 23.32% |
| 2018 FY | -64.96 Million SEK | 37.17% |
| 2018 Q4 | -64.96 Million SEK | 12.13% |
| 2018 Q1 | -94.25 Million SEK | 8.85% |
| 2018 Q3 | -73.94 Million SEK | 13.18% |
| 2018 Q2 | -85.16 Million SEK | 9.65% |
| 2017 Q2 | -115.99 Million SEK | 8.97% |
| 2017 Q4 | -103.4 Million SEK | 5.61% |
| 2017 FY | -103.4 Million SEK | 29.12% |
| 2017 Q1 | -127.42 Million SEK | 12.66% |
| 2017 Q3 | -109.55 Million SEK | 5.56% |
| 2016 Q1 | 2.17 Million SEK | 202.55% |
| 2016 Q4 | -145.89 Million SEK | -2170.9% |
| 2016 Q3 | 7.04 Million SEK | 0.0% |
| 2016 FY | -145.89 Million SEK | -6778.6% |
| 2015 Q4 | -2.12 Million SEK | 0.0% |
| 2015 FY | -2.12 Million SEK | 75.63% |
| 2014 FY | -8.7 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ADDvise Group AB (publ) | 1.22 Billion SEK | 102.865% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 102.865% |
| Arcoma AB | -1.12 Million SEK | -3016.046% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 131.988% |
| BICO Group AB (publ) | 927.9 Million SEK | 103.788% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 127.29% |
| CellaVision AB (publ) | -56.94 Million SEK | 38.272% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | -136.264% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -315.708% |
| C-Rad AB (publ) | -127.6 Million SEK | 72.454% |
| Duearity AB (publ) | 10.23 Million SEK | 443.554% |
| Dignitana AB (publ) | 13.07 Million SEK | 368.785% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 33.304% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.65% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | -0.274% |
| Iconovo AB (publ) | -10.75 Million SEK | -226.805% |
| Integrum AB (publ) | -10.47 Million SEK | -235.502% |
| Luxbright AB (publ) | -13.83 Million SEK | -154.087% |
| Mentice AB (publ) | -49.56 Million SEK | 29.084% |
| OssDsign AB (publ) | -162.78 Million SEK | 78.408% |
| Paxman AB (publ) | -11.41 Million SEK | -208.027% |
| Promimic AB (publ) | -50.32 Million SEK | 30.153% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 284.316% |
| SciBase Holding AB (publ) | -27.32 Million SEK | -28.638% |
| ScandiDos AB (publ) | -1.53 Million SEK | -2195.82% |
| Sectra AB (publ) | -772.85 Million SEK | 95.452% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 84.507% |
| Senzime AB (publ) | -139.54 Million SEK | 74.811% |
| SpectraCure AB (publ) | -50.23 Million SEK | 30.029% |
| Stille AB | -178.5 Million SEK | 80.309% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 102.862% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 83.625% |